Clinical effectiveness of tislelizumab combined with gemcitabine/cisplatin (GC) versus GC as adjuvant therapy in high-risk muscle-invasive urothelial carcinoma (MIUC): A real-world study

被引：0
作者：
Tan, X. [1 ]
Wu, Z. [1 ]
Wang, Y. [1 ]
Yao, K. [1 ]
机构：
[1] Sun Yat Sen Univ, Urol, Canc Ctr, Guangzhou, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.10.354
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
218P
引用
收藏
页码：S1560 / S1560
页数：1
相关论文
共 50 条
  • [31] ALTER-UC-007: A prospective phase 2 study of anlotinib with gemcitabine and cisplatin or anlotinib with penpulimab as perioperative treatment for patients with muscle-invasive urothelial carcinoma (MIUC)
    Zhang, H. L.
    Ye, D.
    Zhu, Y.
    EUROPEAN UROLOGY, 2023, 83 : S749 - S749
  • [32] COST-EFFECTIVENESS ANALYSIS OF NIVOLUMAB AS AN ADJUVANT TREATMENT OF MUSCLE-INVASIVE UROTHELIAL CARCINOMA AT HIGH RISK OF RECURRENCE IN GREECE
    Ni, L.
    Diamantogiannis, F.
    Teitsson, S.
    Knight, C.
    VALUE IN HEALTH, 2022, 25 (12) : S120 - S120
  • [33] ALTER-UC-007: A prospective phase 2 study of anlotinib with gemcitabine and cisplatin or anlotinib with penpulimab as perioperative treatment for patients with muscle-invasive urothelial carcinoma (MIUC).
    Zhang, Hailiang
    Zhu, Yiping
    Ye, Ding-Wei
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [34] Randomized phase II trial of gemcitabine, avelumab and carboplatin versus no neoadjuvant therapy preceding surgery for cisplatin-ineligible muscle-invasive urothelial carcinoma (MIUC): SWOG GAP trial (S2011).
    Sonpavde, Guru P.
    Plets, Melissa
    Liss, Michael A.
    Meeks, Joshua J.
    Petrylak, Daniel P.
    Cole, Suzanne
    McKay, Rana R.
    Gupta, Shilpa
    Hita, Sandi
    Pereira, Taj
    Bangs, Rick
    Tangen, Catherine
    Thompson, Ian Murchie
    Lerner, Seth P.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [35] INTerpath-005: Phase II study of pembrolizumab (pembro) with V940 (mRNA-4157) versus pembro with placebo (pbo) for adjuvant treatment of resected high-risk muscle-invasive urothelial carcinoma (MIUC)
    Sonpavde, G. P.
    Perez Valderrama, B.
    Chamie, K.
    Gupta, S.
    De Santis, M.
    Meehan, R.
    Posadas, T.
    Ren, Y.
    Bavle, A.
    Powles, T. B.
    ANNALS OF ONCOLOGY, 2024, 35 : S1164 - S1164
  • [36] Molecular features underlying response to neoadjuvant gemcitabine, cisplatin, and sorafenib (S-GC) in muscle-invasive urothelial bladder carcinoma (MIBC): Insights for trials of new agents combined with chemotherapy in the field
    Necchi, Andrea
    Raggi, Daniele
    Busico, Adele
    De Cecco, Loris
    Giannatempo, Patrizia
    Nicolai, Nicola
    Piva, Luigi
    Biasoni, Davide
    Catanzaro, Mario
    Torelli, Tullio
    Stagni, Silvia
    Calareso, Giuseppina
    Togliardi, Elena
    Colecchia, Maurizio
    Mariani, Luigi
    Salvioni, Roberto
    Paoli, Alessandro
    Daidone, Maria Grazia
    Sensi, Marialuisa
    Perrone, Federica
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [37] ASSESSING THE IMPACT OF ADDITIONAL FOLLOW-UP FROM THE CHECKMATE-274 TRIAL ON THE COST-EFFECTIVENESS (CE) PROFILE OF NIVOLUMAB VERSUS SURVEILLANCE IN HIGH-RISK, MUSCLE-INVASIVE UROTHELIAL CARCINOMA (MIUC)
    Chandler, T.
    Orsini, I
    Van Beurden-Tan, C.
    Kurt, M.
    Patel, M.
    Teitsson, S.
    VALUE IN HEALTH, 2023, 26 (12) : S187 - S187
  • [38] Cost-effectiveness (CE) of nivolumab (NIVO) as adjuvant treatment of muscle invasive urothelial carcinoma at high risk of recurrence (MIUC-HR) in France
    Negrier, M. S.
    Colrat, F. P.
    Bonastre, J.
    Chamielec, C.
    Teitsson, S.
    Knight, C.
    Ni, L.
    Chevalier, J.
    Gaudin, A-F.
    Roupret, M.
    Branchoux, S.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1339 - S1340
  • [39] Cost-effectiveness of nivolumab compared with surveillance for adjuvant treatment of muscle-invasive urothelial carcinoma at high risk of recurrence in France
    Sylvie Negrier
    Julia Bonastre
    Florian Colrat
    Siguroli Teitsson
    Christopher Knight
    Lei Ni
    Julie Chevalier
    Sébastien Branchoux
    Morgan Rouprêt
    World Journal of Urology, 43 (1)
  • [40] First results from the phase 3 CheckMate 274 trial of adjuvant nivolumab vs placebo in patients who underwent radical surgery for high-risk muscle-invasive urothelial carcinoma (MIUC).
    Bajorin, Dean F.
    Witjes, Johannes Alfred
    Gschwend, Jurgen
    Schenker, Michael
    Valderrama, Begona P.
    Tomita, Yoshihiko
    Bamias, Aristotelis
    Lebret, Thierry
    Shariat, Shahrokh
    Park, Se Hoon
    Ye Dingwei
    Agerbaek, Mads
    Collette, Sandra
    Unsal-Kacmaz, Keziban
    Zardavas, Dimitrios
    Koon, Henry B.
    Galsky, Matt D.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
12345